#NICE #chroniclymphocyticleukaemia #CLL #leukaemia #NICEdraftguidance #CLLpatients #pirtobrutinib #Jaypirca #EliLilly #relapsedCLL #refractoryCLL #tabletathome #hospitalvisits #Pirtobrutinib #NICEdraftrecommendation #Brutonstyrosinekinaseinhibitor #BTKinhibitor #BTKinhibitortreatment
zurl.co/UoNBb
zurl.co/UoNBb
New take at home drug recommended for people with chronic lymphocytic leukaemia
www.nice.org.uk
April 20, 2026 at 10:40 AM
#NICE #AZ #Lokelma #nephrology #AstraZeneca #hyperkalaemia #NHS #NICEcosteffectivenessthreshold #realworldevidence #reimbursement #NICEdraftguidance #persistenthyperkalaemia #chronickidneydisease #CKD #heartfailure #RAASinhibitors #RAASinhibitortherapies #TomKeithRoach #RWEdata
zurl.co/nl7Fy
zurl.co/nl7Fy
NICE update doubles eligible patients for AZ's Lokelma
AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
pharmaphorum.com
April 14, 2026 at 8:42 AM
#neurology #NICE #Biogen #natalizumab #Tysabri #multiplesclerosis #MS #activerelapsingremittingmultiplesclerosis #biosimilar #NICEdraftguidance #Sandoz #PolpharmaBiologics #biosimilarequivalent #Tyruko #activerelapsingremittingMS #rapidlyevolvingsevereMS #biosimilarmedicines
zurl.co/tsiGu
zurl.co/tsiGu
NICE recommends wider use of Biogen MS drug via NHS
NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.
pharmaphorum.com
January 5, 2026 at 11:19 AM
#NHSdiabetesstrategy #GLP1 #NHS #type2diabetes #personalisedapproach #expandedaccess #GLP1agonisttherapies #NHScosts #Individualisedcare #NICEdraftguidance #NICE #SGLT2inhibitors #GLP1receptoragonists #NICEguidance #NHS10Yearplan #patientadvocacy #DiabetesUK
pharmaphorum.com/news/new-nhs...
pharmaphorum.com/news/new-nhs...
New NHS diabetes strategy could raise GLP-1 drug use
New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments
pharmaphorum.com
September 3, 2025 at 8:20 AM
#biotech #neurology #neurologicaldisorders #Leqembi #lecanemab #NICEdraftguidance #NICE
#EisaiEuropeLtd #Eisai #BiogenIdecLtd #Biogen #MHRA #dementia #Alzheimersdisease #AD #costeffectiveness #NHSEngland #NHSWales #patientaccess #reimbursement #valueofmedicines
pharmatimes.com/news/leqembi...
#EisaiEuropeLtd #Eisai #BiogenIdecLtd #Biogen #MHRA #dementia #Alzheimersdisease #AD #costeffectiveness #NHSEngland #NHSWales #patientaccess #reimbursement #valueofmedicines
pharmatimes.com/news/leqembi...
Leqembi enters second consultation period following NICE draft guidance update - PharmaTimes
NICE convenes third committee meeting for additional appraisal consideration
pharmatimes.com
March 6, 2025 at 12:15 PM